Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with223Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the223Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations.
Diagnostics (Basel, Switzerland). 2018 Feb 27*** epublish ***
Anna Maria Mangano, Massimiliano Pacilio, Pasquale Ialongo, Alessandro Semprebene, Guido Ventroni, Lucio Mango
Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. ., Medical Physics Unit, "Policlinico Umberto I" University Hospital, 00161 Rome, Italy. ., Radiology, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. ., Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. ., Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. ., Nuclear Medicine Department, "S. Camillo-Forlanini" General Hospital, 00152 Rome, Italy. .